INMD
InMode Ltd.
Healthcare · Medical Devices · NMS
$13.54
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 100.0%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$840M
Total market value of the company
10.23
Reasonably valued
9.35
Based on estimated future earnings — lower means cheaper
Rev Growth
+5.3%
Year-over-year revenue change
Profit Margin
23.3%
How much profit the company keeps from each dollar of revenue
13.6%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$14.50
+7% from current price — median analyst estimate
Recommendation
HOLD
Consensus view from 4 analysts covering this stock
About InMode Ltd.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.

https://www.inmodemd.com

Country: Israel Employees: 660 Industry: Medical Devices
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

MARKDOWN
Price trending down — defensive positioning
-0.172
Returns do not compensate for the risk — negative edge
-0.0290
No positive edge detected — the data suggests staying out
-0.390
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-13.5%
Historical annualised return based on price data
-34.7%
Largest peak-to-trough decline — the worst it has been
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
12
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

1.98
Significantly more volatile than the market
52W High
$16.74
19% below the year high
52W Low
$12.72
6% above the year low
Avg Volume
931,506
Average daily shares traded — higher means easier to buy and sell
3.9
Days it would take all short sellers to cover — higher means more crowded
Short % Float
5.4%
Moderate short interest
N/A
Annual dividend as a percentage of the share price
$1.35
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

0.73
Moderate leverage — manageable
8.80
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
7.47
Like current ratio but excludes inventory — stricter test
Gross Margin
77.8%
Revenue left after cost of goods — higher means pricing power
Operating Margin
12.3%
Profit from core operations before interest and tax
$44M
Positive — the business generates more cash than it spends
Revenue (TTM)
$375M
Total revenue over the last 12 months
Net Income
$87M
Profitable — the bottom line is positive
Analyst Coverage
Analysts
4
Target High
$19.00
Target Median
$14.50
Target Low
$14.00
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.